RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.Read More
Closely held Braeburn Pharmaceuticals announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) code, or permanent J-code, for Probuphine, the first and only six-month buprenorphine implant for the maintenance treatment of opioid addiction.Read More
Leerink resumed coverage of Invitae (NASDAQ:NVTA) with an “outperform” rating and $12 price target. The stock closed at $8.44 on Wednesday.
Analyst Puneet Souda writes that Invitae is a high growth, commercial-stage diagnostics company focused on building a business around genetic testing in a sizable and growing multibillion-dollar market.Read More
Stifel launched coverage of Tabula Rasa HealthCare (NASDAQ:TRHC) with a “buy” rating and $17 price target. The stock closed at $14.23 on Friday.
Tabula is a healthcare information technology company focused on medication management solutions created from equal parts data and science, and aimed, when appropriate, at the individual using genetic information.Read More
BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday.
Cerus is a biomedical products company focused on the field of blood safety.Read More